In this study, we found that PI3K/AKT/mTOR inhibitors upregulated MIF expression and secretion in several PTEN-deficient cancer cells, and activated STAT3 activity through JAK1, eventually limiting the effects of these inhibitors. The gene discussed is MTOR; the disease is cancer.